North America Diabetes Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The north america diabetes drugs market size was valued at USD 42.08 billion in 2025 and estimated to grow from USD 44.28 billion in 2026 to reach USD 57.08 billion by 2031, at a CAGR of 5.22% during the forecast period (2026-2031). This report is Segmented by Drug Class (Insulins [Biosimilar Insulin and More], Non-Insulin Injectable, Oral Anti-Diabetic and Combination Drugs), Diabetes Type (Type 1 Diabetes and Type 2 Diabetes), Drug Origin (Branded and Generic/Biosimilar), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and More) and Geography. The Market Forecasts are Provided in Terms of Value (USD).

North America Diabetes Drugs Market Trends and Insights

Increasing adoption of GLP-1 agonists in obese T2DM

GLP-1 receptor agonists unify obesity and diabetes management, a nexus relevant to more than 88% of people with Type 2 diabetes. Tirzepatide reached roughly 12% prescription share of glucose-lowering drugs by end-2023, and its popularity among non-diabetic weight-management users underscores the therapeutic blur between metabolic indications. Dual GLP-1/GIP activity delivers greater body-weight and HbA1c reductions than single-target drugs, while emerging triple-agonists such as retatrutide have posted 24% weight loss at 48 weeks, setting new clinical benchmarks. Fast-tracked FDA approvals for wider cardiometabolic indications are expanding reimbursement horizons and encouraging prescribers to adopt these therapies earlier in care pathways.

Reimbursement expansion for dual & triple incretins

Payers are recalibrating formularies to recognize the cardiovascular and renal benefits of dual and triple incretins. Medicare’s price negotiations apply greater pressure on legacy oral agents, while newer GLP-1s gain Tier-preferred coverage, thus lowering out-of-pocket costs for seniors.Commercial insurers now classify obesity as a medical condition, unlocking pharmacotherapy budgets previously reserved for diabetes. Employer health plans are bundling obesity and diabetes care contracts tied to outcome metrics, reinforcing utilization growth.

Payer prior-authorization throttles GLP-1 volumes

US payers continue to impose multi-step therapy rules that delay or deny GLP-1 initiation despite favorable clinical profiles, leading to patient drop-out and slower overall market penetration. Medicare Advantage plans remain especially cautious in approving weight-management uses, preserving utilization caps that curb early growth.

Other drivers and restraints analyzed in the detailed report include:

• Biosimilar insulin price wars accelerate uptake
• CGM-linked dosing algorithms spur drug adherence
• API tariff risk from China supply concentration

Segment Analysis

Oral agents secured 67.72% of the North America diabetes drugs market in 2025 and are projected to expand at 4.87% CAGR through 2031, sustaining leadership despite injectable breakthroughs. SGLT-2 inhibitors such as canagliflozin continue to gain based on cardio-renal outcome data and Health Canada labeling updates.

Non-insulin injectables are climbing rapidly on the back of GLP-1, dual GIP/GLP-1, and emerging triple-agonist classes. Triple-mechanism drugs are positioned as premium therapies offering weight, cardiovascular, and renal benefits, thereby lifting value per prescription within the North America diabetes drugs market. Alpha-glucosidase inhibitors retain a niche among geriatric cohorts, and combination pills that merge multiple mechanisms aim to simplify dosing and boost adherence.

Therapies for Type 2 diabetes continue to dominate revenue, yet Type 1 options are showing the strongest incremental gains. Integration of weekly semaglutide with automated insulin delivery lifted time-in-range metrics from 69.4% to 74.2%, a meaningful clinical advance. The resulting enthusiasm is expanding the North America diabetes drugs market size for Type 1 adjuncts. Gene-therapy programs aimed at beta-cell regeneration are still pre-commercial but underscore the pipeline depth.

Complete Report Scope:

• By Drug Class
  • Insulins
    • Basal / Long-acting
    • Bolus / Fast-acting
    • Traditional Human Insulin
    • Biosimilar Insulin
  • Non-Insulin Injectables
    • GLP-1 Receptor Agonists
    • Dual / Triple Agonists (e.g., Tirzepatide, Retatrutide)
    • Amylin Analogues
  • Oral Anti-Diabetics
    • Biguanides
    • SGLT-2 Inhibitors
    • DPP-4 Inhibitors
    • Alpha-Glucosidase Inhibitors
    • Sulfonylureas
    • Meglitinides
    • Thiazolidinediones
  • Combination Drugs
• By Diabetes Type
  • Type 1 Diabetes
  • Type 2 Diabetes
• By Drug Origin
  • Branded
  • Generic / Biosimilar
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Geography
  • United States
  • Canada
  • Mexico

List of Companies Covered in this Report:

• Novo Nordisk
• Eli Lilly and Company
• Sanofi
• AstraZeneca
• Merck
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Pfizer
• Johnson & Johnson
• Takeda Pharmaceuticals
• Teva Pharmaceutical Industries
• Astellas Pharma
• GlaxoSmithKline
• Amgen
• Viatris
• MannKind
• Adocia SA
• Innovent Biologics
• Sun Pharmaceuticals Industries

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support